NCT01130961
Completed
Not Applicable
Management of Advanced Non-Small Cell Lung Cancer and Clinical Outcomes in Patients Who Received Gefitinib (IRESSA) in Tertiary Care Setting in Thailand
ConditionsLung Cancer
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 104
- Locations
- 1
- Primary Endpoint
- Progression-free survival
Overview
Brief Summary
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed as having lung cancer based on histological/cytological findings
- •Admitted to the hospital between January 2004 and December 2008
- •Treated with gefitinib for at least 3 months
Exclusion Criteria
- •Involvement in the planning and/or conduct of the study
- •Participation in another clinical study during the last 3 months
Outcomes
Primary Outcomes
Progression-free survival
Time Frame: median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.
Secondary Outcomes
- Time to maximum response(Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx.)
- Overall survival(time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx.)
- Prevalence of EGFR & KRAS mutation from laboratory result(During Jan 2004- Dec 2008 or 5 years approx.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Suspended
Phase 3
EGF vaccine- Advanced Lung tumorson Small Cells Lung CancerRPCEC00000161Centre of Molecular Immunology (CIM)579
Completed
Not Applicable
Chemotherapy in Treating Patients With Lung CancerNon Small Cell Lung CancerNCT01067794Eli Lilly and Company1,610
Not yet recruiting
Not Applicable
Designing information for lung cancer patients in decision making.Patients presenting with a stage I non-small cell lung cancer (NSCLC).Patienten met stadium I niet kleincellige longkanker.NL-OMON2116225
Unknown
Not Applicable
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine KinaseNon-Small-Cell Lung CancerNCT02755337Dr. Soetomo General Hospital70
Completed
Not Applicable
Non-small Cell Lung Cancer and Quality of LifeNon Small Cell Lung CancerNCT00818402University of Turku130